The naive question: you keep seeing 'co-agonist' in obesity-drug coverage. What does it mean? An agonist is a molecule that switches a receptor on. A co-agonist switches on more than one — with a single molecule.
Here's why that's hard. Each receptor in your body evolved to recognize one specific hormone, like a lock shaped for one key. A co-agonist has to be a single key that opens two or three different locks at once. Designing one molecule with that many right-fitting features is a real feat of protein engineering.
Think of it like a master key cut to work several doors. Each tooth has to be exactly right for its lock, but they all share one body. A co-agonist peptide is engineered the same way — different regions of the same molecule fit different receptors.
The 2022 patents show the range. Hanmi's grant US11332508B2 covers a triple agonist hitting glucagon, GLP-1, and GIP receptors — one key, three locks. Zealand's US11395847B2 covers dual GLP-1/GLP-2 agonists — one key, two locks.
Why bother? Because the body's metabolism is controlled by several hormone signals, and hitting them together does more than hitting one. A co-agonist lets a single injection do the work that would otherwise need a cocktail of separate drugs.
The short version: a co-agonist is one molecule, multiple receptors. The cleverness is in the engineering — building a single peptide that fits several locks at once — and the 2022 patent record is where that craft is on full display.